GlassScriptPhysician profile
Jeffrey Trost
NPI 1265483242
$6,957.54
in general payments reported to CMS, 2019-2025
32 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,248 · 2020: $1,562 · 2021: $1,871 · 2022: $1,003 · 2023: $149 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,132.37 | 2019-2022 | |
| Novo Nordisk INC | $942.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $668.33 | 2019-2023 | Arexvy |
| Abbvie INC. | $520.93 | 2021-2023 | Qulipta |
| Allergan, INC. | $433.08 | 2019-2021 | |
| Pfizer INC. | $429.81 | 2019-2021 | |
| Lilly USA, LLC | $388.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $352.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $312.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $223.73 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $214.96 | 2021 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Amarin Pharma, INC. | $102.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $100.23 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $96.31 | 2019-2022 | |
| Amgen INC. | $72.36 | 2020-2021 | |
| Astellas Pharma US INC | $64.29 | 2019-2021 | |
| Lundbeck LLC | $64.28 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.25 | 2022 | |
| Organon LLC | $45.86 | 2021-2022 | |
| Genentech USA, INC. | $41.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $34.38 | 2019-2020 | |
| Tris Pharma INC | $33.97 | 2021-2022 | |
| Shire North American Group INC | $27.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.35 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.12 | 2021 | |
| Eisai INC. | $18.33 | 2020 | |
| Supernus Pharmaceuticals, INC. | $17.89 | 2021 | |
| Vistapharm, INC. | $13.39 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Trost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.